ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,084.47
-0.62%
US Tech 100
17,158.80
-0.87%
Dow Jones
38,092.96
-0.76%
Brent Oil
86.285
-1.15%
Bitcoin
60,416.19
-5.36%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. UroGen Pharma Ltd (URGN) Quote

UroGen Pharma Ltd

UroGen Pharma Ltd (URGN)

NASDAQ
13.94
-0.10
( -0.71% )
Updated: 12:07:28
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
13.94
Bid
13.94
Ask
14.00
Volume
69,676
13.84 Day's Range 14.15
8.69 52 Week Range 24.13
Market Cap
476.344M
Previous Close
14.04
Open
14.00
Last Trade
3
@
13.94
Last Trade Time
12:08:51
Financial Volume
$ 974,746
VWAP
13.9897
Average Volume (3m)
360,581
Shares Outstanding
34,122,087
Dividend Yield
-
PE Ratio
-4.66
Earnings Per Share (EPS)
-3
Revenue
82.71M
Net Profit
-102.24M

About UroGen Pharma Ltd

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.urogen.com
Headquarters
Ra'anana, Center, Isr
Founded
1970
UroGen Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker URGN. The last closing price for UroGen Pharma was $14.04. Over the last year, UroGen Pharma shares have traded in a share price range of $ 8.69 to $ 24.13.

UroGen Pharma currently has 34,122,087 shares outstanding. The market capitalization of UroGen Pharma is $476.34 million. UroGen Pharma has a price to earnings ratio (PE ratio) of -4.66.

URGN Latest News

More News

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

Subgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) Three independent long-term...

April 17 2024
Business Wire

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024 Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten...

April 15 2024
Business Wire

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a...

April 03 2024
Business Wire

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

Initiated submission of a rolling NDA to the FDA for UGN-102; 12-month duration of response data from ENVISION expected to support completion of NDA submission Announced next-generation novel...

March 14 2024
Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of...

March 08 2024
Business Wire

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

Conference Call and Webcast Scheduled for Thursday, March 14, 2024, at 10:00 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative...

March 04 2024
Business Wire

Form 8-K - Current report

March 04 2024
Edgar (US Regulatory)

Form 8-K - Current report

March 01 2024
Edgar (US Regulatory)

UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference

- Presentation March 4, 2024 at 1:30 PM ET - UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

February 26 2024
Business Wire

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

February 12 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.46-3.1944444444414.414.8513.6916664214.15622163CS
4-0.34-2.3809523809514.2815.512.3729773214.24964298CS
12-1.96-12.327044025215.919.8712.3736058116.18783202CS
262.7624.68694096611.1819.8710.6331650215.18187679CS
522.3520.276100086311.5924.138.6937996316.15216156CS
156-6.06-30.32024.134.8520617914.03593708CS
260-22.79-62.047372719836.7339.974.8519958018.53189298CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AKLIAkili Inc
$ 0.4239
(80.46%)
72.88M
GMMGlobal Mofy Metaverse Ltd
$ 1.48
(59.09%)
68.81M
WGSGeneDx Holdings Corporation
$ 16.215
(47.41%)
4.88M
CYCCCyclacel Pharmaceuticals Inc
$ 1.96
(44.12%)
18.14M
AGBAAGBA Group Holding Ltd
$ 3.38
(43.83%)
79.9M
CETXCemtrex Inc
$ 1.2499
(-29.78%)
254.83k
LICNLichen China Limited
$ 1.46
(-28.08%)
898.5k
NRXPNRX Pharmaceuticals Inc
$ 2.6577
(-25.14%)
671.21k
CSLRComplete Solaria Inc
$ 0.59
(-19.20%)
1.95M
LUCYInnovative Eyewear Inc
$ 0.195
(-19.05%)
365.68k
AGBAAGBA Group Holding Ltd
$ 3.38
(43.83%)
79.9M
EGOXNext e GO NV
$ 0.034
(23.19%)
79.24M
JAGXJaguar Health Inc
$ 0.2313
(11.20%)
73.58M
AKLIAkili Inc
$ 0.4239
(80.46%)
72.88M
TSLATesla Inc
$ 184.79
(-4.77%)
71.62M

Discussion

View Full Feed
SmokeSignals SmokeSignals 48 seconds ago
bleg did well. what's next?😬
NickyCapone NickyCapone 50 seconds ago
I’m at the sushi bar for lunch

Hope everybody enjoys their lunch
Bon appétit

…be back after lunch
CBIA
NickyCapone NickyCapone 51 seconds ago
I’m at the sushi bar for lunch

Hope everybody enjoys their lunch
Bon appétit

…be back after lunch
CBIA
PROPHET-of-PROFITS PROPHET-of-PROFITS 1 minute ago
done.
BLEG
wingnutt01 wingnutt01 1 minute ago
YEA!! and, and, it's obvious where J FedderWoman received the majority of his votes.
Correct Penn? zI say "correct" because obviously something about Fedderman (Aint) RIGHT!
FNMA
Sirpeter Sirpeter 1 minute ago
You and I won't be around enough yrs for that ...but yeah, maybe by 2070 robots will be drinking that Blue Heaven shi...
CBIA
trd4profit trd4profit 1 minute ago
Yeah..I didn't catch that before..hmm
RNVA
fnyack fnyack 1 minute ago
Not a single share exchanged hands today so far, sell in May and go away, but it’s still April.
SLDC
JettaR JettaR 2 minutes ago
Ai bots are doing their job!!
CBDW
pdmihopefull pdmihopefull 2 minutes ago
9 million shares sold...2million buys..you homeless2020... lmao...
KGKG
Pro_v12001 Pro_v12001 2 minutes ago
Agreed Dude and the Mark L's of the world and even Andy B will be surprised by EO Polymer made by Lightwave Logic. Fully scalable and ready to roll. Maybe NDA's do work!
LWLG
Riverheaddaddy Riverheaddaddy 2 minutes ago
If they r/s, that’s telling the loyal bag holders to take a hike. Then they will try to suck in newbie’s. All I can say is prove me wrong. Surprise me . Come out with new name, audits. Huge buyback. Lol
CBDD
Tiger Money Tiger Money 3 minutes ago
Lunchtime apparently
AGBA
docsetc docsetc 3 minutes ago
ohh, funny.....
ENZC
King James 1 King James 1 3 minutes ago
Another dip, another buying opportunity. Was able to catch a few shares at 0.856 and now we are back to 0.9
If we ever get a break from the fed without tripping off more inflation we will be in a position to fly! Thanks for the posts today!
FCEL
Snd101 Snd101 3 minutes ago
Thanks for sharing your thought process. I agree that approval by France, Germany and Italy is one of the major keys to success for Amarin. Is the path to get there is via running custom trial that these three country would like? I am not so sure. It would be a surprise if those three countries agre
AMRN
powerbattles powerbattles 3 minutes ago
It will happen and your broker will handle all the transactions for you.
EMGE
igotthemojo igotthemojo 3 minutes ago
"For the past 2 months"

hmmmm...why only the past 2 months?...lets take a look...

oh right!...cause in Feb the pps ran from 4 cents to 15 cents on big volume...with buys far exceeding sells...and now the pps is consolidating between .07 and .10, waiting for the next big
KBLB
GregLechuga GregLechuga 3 minutes ago
.0059 is very close!
BLEG
Filterthenoise Filterthenoise 3 minutes ago
Interesting.
RNVA
Nick2424 Nick2424 3 minutes ago
Up until March 2024, dutv had 250m class B preferred shares authorized per Delaware SOS and the quarterly filings but those never showed up on OTCM as authorized shares, so you don’t know that those preferred class C shares will show up as authorized shares.

You know full well that a
DUTV
Tiger Money Tiger Money 3 minutes ago
Are you shorting them down to fair value? I’m too much off a wus
AGBA
Bubae Bubae 3 minutes ago
Of course you are. You have been calling for dollars since this was above a penny. The 52 week high of $0.0128 was November 27th and you claimed to own "...a sizeable amount of the float..." on the 29th? Wow, how much will you be down when the dilution begins again in earnest?


BEGI

Your Recent History

NASDAQ
URGN
UroGen Pharma
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved